U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

Substitute for form 1449/PTO			C	Complete if Known			
	INFORMATION I	DISCLOSURE	Application Number	10/576,794	PAR		
	STATEMENT BY	APPLICANT	Filing Date	10/25/2004	70		
	D 1 0 1 24 1 November 40 0040		First Named Inventor	Abdessatar Chtourou	/ %		
Date Submitted: November 18, 2010		Art Unit	1656	NOV 1.8 2010			
	(use as many shee	ts as necessary,	Examiner Name	Marsha M. TSAY	101   0 2010		
Sheet	1	of 1	Attorney Docket Number	096183-0103	图 4		

			U.S. PATENT DO	CUMENTS	
Examin er Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		Number-Kind Code <sup>2</sup> (if known)			Passages or Relevant Figures Appear
	A1	2003/0232969 A1	12/18/2003	LENGSFELD ET AL.	
	A2	2009/0176709 A1	07/09/2009	NIETO ET AL.	
	A3	5,522,991	06/04/1996	TUCCELLI ET AL.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code <sup>2</sup> (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

			FOREIGN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	A4	WO 96/00237 A1	01/04/1996	PHARMACIA AB		
	A5	EP 1 348 445 A1	10/01/2003	AVENTIS BEHRING GMBH		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ <sup>6</sup>
	A6	KRIEZEK ET AL., "A Rapid Method to Visualize von Willebrand Factor Multimers by Using Agarose Gel Electrophoresis, Immunolocalization and Luminographic Detection," <i>Thrombosis Research</i> , Vol. 97, pp. 457-462, 2000.	
	A7	BURNOUF-RADOSEVICH ET AL., "Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates," <i>Vox Sang</i> , Vol. 67, pp. 132-138, 1994.	
,	A8	FELDMAN ET AL., "Improved Safety from Plasma Derivatives: Purification and Viral Elimination Characteristics of Mononine," <i>Acta Haematol.</i> , Vol. 94 (suppl.), pp. 25-34, 1995.	
	A9	BURNOUF ET AL., "Nanofiltration of plasma-derived biopharmaceutical products," <i>Haemophilia</i> , Vol. 9, pp. 24-37, 2003.	

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Traislation is adactived.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: